ZIOP News Alert Ziopharm Oncology Inc (ZIOP) 4.76 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ziopharm Oncology Inc (ZIOP) 4.76 $ZIOP

Biotech Equities Technical Analysis -- Incyte, ZIOPHARM Oncology, Hemispherx Biopharma, Infinity Pharma, and Orexigen Therapeutics
PR Newswire - Fri Dec 19, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Hemispherx Biopharma Inc. (NYSE MKT: HEB), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 18, 2014, rallied as the Dow Jones Industrial Average finished at 17,778.15, up 2.43% and the NASDAQ Composite closed at 4,748.40, up 2.24%. The S&P 500 finished the session 2.40% higher at 2,061.23. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 813.60, up 2.77%, with the index advancing 8.37% in the previous three months. Register for your complimentary reports on these five stocks at:
OREX: 5.98 (+0.01), ZIOP: 4.76 (+0.07), HEB: 0.22 (-0.02), INCY: 71.57 (+1.99), INFI: 16.65 (+0.37)

ZIOPHARM and Intrexon Present Clinical and Preclinical Data From Immuno-Oncology Programs at AACR Tumor Immunology and Immunotherapy Meeting
GlobeNewswire - Wed Dec 03, 11:30AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the presentation of clinical and preclinical studies from their immuno-oncology programs at the American Association for Cancer Research (AACR) 2014 Immunology and Immunotherapy Meeting taking place December 1-4, 2014 in Orlando, Florida. Presentations include:
ZIOP: 4.76 (+0.07), XON: 26.19 (+0.67)

Increased Earnings Estimates Seen for ZIOPHARM Oncology (ZIOP): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 7:46AM CST
ZIOPHARM Oncology could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ZIOP: 4.76 (+0.07)

Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma, ZIOPHARM Oncology, Arena Pharma, and Regulus Therapeutics
PR Newswire - Wed Nov 19, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regulus Therapeutics Inc. (NASDAQ: RGLS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 18, 2014, the NASDAQ Composite ended at 4,702.44, up 0.67%, the Dow Jones Industrial Average advanced 0.23%, to finish the day at 17,687.82, and the S&P 500 closed at 2,051.80, up 0.51%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 1.58%, with the index also advancing 12.08% in the last one month. Register for your complimentary reports on these five stocks at:
ZIOP: 4.76 (+0.07), LXRX: 0.90 (+0.02), IMGN: 5.90 (+0.13), RGLS: 14.78 (+0.24), ARNA: 3.57 (-0.01)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:46AM CST

ZIOP: 4.76 (+0.07), BSPM: 1.09 (-0.03), BDR: 2.36 (+0.06), ZAZA: 3.20 (+0.70), ACY: 8.50 (-0.05), NBS: 3.27 (+0.02), SYRX: 1.14 (+0.11), IAG: 2.41 (+0.06), THTI: 1.32 (+0.14), BITA: 72.57 (+0.36), VRTB: 3.49 (-0.12), OPTT: 0.63 (-0.01), INVT: 0.63 (+0.04), GERN: 3.06 (+0.05), VASC: 27.30 (+0.71), LOCM: 1.15 (+0.03), CTHR: 1.63 (-0.03), MOV: 27.58 (-0.41), IFON: 1.07 (-0.06), SVM: 1.25 (+0.09)

More on Ziopharm Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 11:49AM CDT

ZIOP: 4.76 (+0.07)

Ziopharm posts 3Q loss
Automated Insights - Fri Oct 31, 4:04AM CDT
NEW YORK (AP) _ Ziopharm Oncology Inc. (ZIOP) on Friday reported a loss of $6.1 million in its third quarter.
ZIOP: 4.76 (+0.07)

ZIOPHARM Reports Third-Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 30, 3:50PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the third quarter ended September 30, 2014, and provided an update on the company's product development activities.
ZIOP: 4.76 (+0.07), XON: 26.19 (+0.67)

ZIOPHARM Oncology EPS of -$0.06
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:11PM CDT

ZIOP: 4.76 (+0.07)

ZIOPHARM Oncology (ZIOP) Jumps: Stock Moves Up 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 7:51AM CDT
ZIOPHARM Oncology, Inc. (ZIOP) was a big mover last session, as its shares rose nearly 6% on the day.
MDVN: 99.23 (+1.23), MACK: 10.91 (+0.36), ZIOP: 4.76 (+0.07), ILMN: 186.22 (+2.72)

Global Gene Therapy Market & Pipeline Insight Report 2014 - Analysis of 315 Drug therapy Pipelines for the $500 Million Market
M2 - Fri Oct 17, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nk3sv/global_gene) has announced the addition of the "Global Gene Therapy Market & Pipeline Insight" report to their offering. The global market opportunity for gene therapy is expected to reach USD 500 million by 2020 There have been significant advancements in the area of gene therapy in terms of research of new drugs. Over the past 20 years, the gene therapy market has witnessed significant advances ranging from the stage of conception, to the current stage of clinical trials for various disease conditions. When compared to other conventional methods such as radiotherapy and chemotherapy, gene therapy enjoys a clear advantage mainly because this therapy does not inhibit the immune system. Also, there has been an increased use of innovative technologies, which has led to an expansion of the scope of gene therapy worldwide. The growth of this market greatly depends on the regulatory approval of products which are currently in clinical trials. A major part of the gene therapy products for cancer and cardiovascular diseases are currently in Phase II and Phase III of clinical trials. Other factors impacting the gene therapy market are the cost of the treatment and the disease population under study. Additionally, funding and developments in research coupled with acceptance of gene therapy products to use in medicine are also expected to impact the market in the near future. Although the initial studies of gene therapy were conducted mostly on monogenetic diseases, the focus of the scientists rapidly shifted towards cancer. This increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for dominant share in the overall clinical trials being conducted. The major reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer. Global Gene Therapy Market & Pipeline Insight Market Highlight: - Gene Therapy Market Overview - Significance of Gene Therapy in Cancer Therapeutics - Current Applications of Gene Therapy to Cancer Treatment - Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook - FDA & AMA Guidelines for Gene Therapy - Gene Therapy Pipeline by Phase, Indications, Country & Company - Gene Therapy Pipeline: 246 Drugs - Marketed Gene Therapy: 2 (Gendicine & Rexin-G) - Cancer Gene Therapy Pipeline: 69 Drugs Key Topics Covered: 1. Introduction to Gene Therapy 2. Gene Therapy Classification 3. Mechanism of Gene Therapy 4. Global Gene Therapy Market Overview 5. Significance of Gene Therapy in Cancer Therapeutics 6. Current Applications of Gene Therapy to Cancer Treatment 7. Global Gene Therapy Market Dynamics 8. Gene Therapy Market Future Growth Outlook 9. EMA Guidelines for Gene Therapy 10. FDA Guidelines for Gene Therapy 11. Gene Therapy Pipeline by Phase, Indications, Country & Company 12. Marketed Gene Therapies by Indications, Country & Company 13. Suspended & Discontinued Gene Therapy in Pipeline 14. Competitive Landscape - Advantagene - BioCancell - Celgene - Epeius Biotechnologies - GenVec - Genethon - Introgen Therapeutics - MultiVir - Shenzhen SiBiono GeneTech - Vical - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/2n...lobal_gene
VICL: 1.03 (+0.02), ZIOP: 4.76 (+0.07), CELGZ: 3.34 (-0.01)

EXH, JJG, GAZ, PZN, ZAGG, ZIOP Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Oct 14, 4:00AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Exterran Holdings Inc (NYSE:EXH), IPATH DJ-UBS GRAINS SUBINDEX (NYSE:JJG), Afriquia Gaz SA (NYSE:GAZ), Pzena Investment Management Inc (NYSE ZN), Zagg Inc (NASDAQ:ZAGG), ZIOPHARM Oncology Inc (NASDAQ:ZIOP) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
EXH: 31.29 (+0.14), PZN: 9.17 (+0.03), ZIOP: 4.76 (+0.07), GAZ: 2.06 (unch), JJG: 39.70 (-0.83), ZAGG: 6.66 (+0.13)

Halloran Consulting Group Expands Services with Physician, Safety Expert, and Head of Regulatory Affairs
Business Wire - Tue Sep 09, 9:00AM CDT
Halloran Consulting Group, Inc. (Halloran) today announced the recent hiring of Greg Shipp, MD, formerly with Regenesis Biomedical where he served as Director of Clinical Research; Laura Giannini, RPh, MBA, previously with Boston Scientific as Director of Process Management; and Mary Matthew, formerly with ZIOPHARM Oncology where she served as Vice President of Regulatory Affairs and Quality.
BSX: 13.13 (+0.07), ZIOP: 4.76 (+0.07)

ZIOPHARM Oncology (ZIOP) in Focus: Stock Rises 10.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 8:39AM CDT
ZIOPHARM Oncology, Inc. (ZIOP) was a big mover last session, as its shares rose over 10% on the day.
CBPO: 64.79 (-0.59), ZIOP: 4.76 (+0.07), CBM: 21.62 (+0.37), GILD: 91.29 (+1.84)

CPLA, SUSS, WWWW, ZIOP, LQDT, QTEC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Sep 04, 9:29AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Capella Education Co (NASDAQ:CPLA), Susser Holdings Corp (NASDAQ:SUSS), Web.Com Group Inc (NASDAQ:WWWW), ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Liquidity Services Inc (NASDAQ:LQDT), First Trust NASDAQ-100- Technology Ix Fd (NASDAQ:QTEC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ZIOP: 4.76 (+0.07), WWWW: 19.23 (-0.03), LQDT: 8.19 (-0.19), CPLA: 74.60 (-0.38), QTEC: 44.59 (+0.01), SUSS: 81.72 (unch)

ZIOPHARM Reports Second-Quarter 2014 Financial Results and Reviews Recent Activities
GlobeNewswire - Thu Aug 07, 3:44PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the second quarter ended June 30, 2014, and provided an update on the company's product development activities.
ZIOP: 4.76 (+0.07), XON: 26.19 (+0.67)

Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax
PR Newswire - Thu Aug 07, 7:50AM CDT
On Wednesday, August 06, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average finished the day 0.08% higher at 16,443.34, and the S&P 500 closed flat at 1,920.24. However the gains were not broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, and the index has declined 2.91% in the last one month. Investor-Edge has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Sangamo BioSciences Inc. (NASDAQ: SGMO), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Dyax Corporation (NASDAQ: DYAX). Free research on these five companies can be accessed at:
MACK: 10.91 (+0.36), ZIOP: 4.76 (+0.07), BMRN: 88.18 (+0.89), SGMO: 14.20 (+0.14), DYAX: 14.13 (+0.30)

ZIOPHARM Oncology and Solasia Pharma Announce Global License and Collaboration Agreement for Darinaparsin
GlobeNewswire - Thu Jul 31, 3:43PM CDT
ZIOPHARM Oncology, Inc. ("ZIOPHARM" (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Solasia Pharma K.K. ("Solasia" , a developer of oncology pharmaceuticals in-licensed for commercialization in major markets throughout the world, announced today an amendment and restatement of their License and Collaboration Agreement for darinaparsin (Zinapar(TM) or ZIO-101) and related organoarsenic molecules.
ZIOP: 4.76 (+0.07)

ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and Clinical Program Update
GlobeNewswire - Tue Jul 22, 6:00AM CDT
-- Expansion of synthetic immuno-oncology programs to include chimeric antigen receptor T-cell (CAR-T) therapy
ZIOP: 4.76 (+0.07), XON: 26.19 (+0.67)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 91

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 88

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 103

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 50

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 111

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Weight Loss Solutions: ASC36 and ASC35 Development

Updated Category News Views 312

Exciting Co-formulation Advancements by Ascletis Pharma Ascletis Pharma Inc. has made a significant stride in obesity treatment with the co-formulation of ASC36, a monthly amylin receptor agonist, and ASC35, a GLP-1R/GIPR dual agonist. These innovative therapies aim to offer better patient outcomes through advanced pharmacokinetic profiles and a robust efficacy in weight...

Continue Reading
Schouw & Co. Reports Steady Q1 Performance Amidst Challenges

Updated Category News Views 291

Overview of Q1 2025 Performance Recently, Schouw & Co. disclosed their interim report for the first quarter of 2025, highlighting a performance that generally met expectations despite ongoing economic turbulence. While the disturbances in the market have generated caution among customers, the direct effects on Schouw & Co.'s operations seem to have been minimal. Key...

Continue Reading
Parker Hannifin to Present at Jefferies Industrials Conference

Updated Category News Views 153

Parker Hannifin Set to Present at the Jefferies Industrials Conference Parker Hannifin Corporation (NYSE: PH), a recognized leader in motion and control technologies worldwide, has announced its participation in the prestigious Jefferies Industrials Conference. This important event will take place in early September, bringing together industry leaders and innovators to...

Continue Reading
374Water Innovatively Enhances Waste Management Solutions

Updated Category News Views 121

Revolutionizing Waste Management with AirSCWO Technology DURHAM, N.C. – 374Water Inc. (NASDAQ: SCWO) is making significant advancements with its innovative AirSCWO technology aimed at revolutionizing waste management practices. The Company has partnered with the Orange County Sanitation District (OC San) to implement its cutting-edge AirSCWO 6 System at their treatment...

Continue Reading
SharpLink Gaming Expands Footprint in Crypto Gaming Market

Updated Category News Views 548

SharpLink Gaming Advances in Crypto Gaming with Strategic Investment SharpLink Gaming, Inc. (NASDAQ: SBET), a notable player in online marketing for sports betting and iGaming, has declared an exciting venture that marks its entry into the rapidly growing crypto gaming sector. Recently, the company secured a 10% equity stake in Armchair Enterprises, the parent company of...

Continue Reading